MARCI ISAAC: Open Payments
NPI 1811353915 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$728 in 31 payments from 13 companies in 2025. Trend: 2023 $918 · 2024 $865 · 2025 $728
Food & beverage: $728
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 5 | $163 |
| CVRx, Inc. | 6 | $136 |
| E.R. Squibb & Sons, L.L.C. | 3 | $72 |
| Novo Nordisk Inc | 3 | $64 |
| Novartis Pharmaceuticals Corporation | 3 | $61 |
| SCPHARMACEUTICALS INC. | 3 | $50 |
| ABIOMED | 1 | $38 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $36 |
| Alnylam Pharmaceuticals Inc. | 1 | $31 |
| Merck Sharp & Dohme LLC | 1 | $22 |
Products named: REPATHA, Barostim Neo System, CAMZYOS, FUROSCIX, Ozempic, LEQVIO, JARDIANCE, AMVUTTRA.
Industry payments across TX — which companies pay providers there.
